Show simple item record

dc.contributor.authorOzkilic, Anil Cagla
dc.contributor.authorDedekarginoglu, Galip
dc.contributor.authorCengiz, Muejgan
dc.contributor.authorOzaydin, Ahmet
dc.date.accessioned2021-03-03T20:18:04Z
dc.date.available2021-03-03T20:18:04Z
dc.date.issued2007
dc.identifier.citationCengiz M., Ozaydin A., Ozkilic A. C. , Dedekarginoglu G., "The investigation of GSTT1, GSTM1 and SOD polymorphism in bladder cancer patients", INTERNATIONAL UROLOGY AND NEPHROLOGY, cilt.39, sa.4, ss.1043-1048, 2007
dc.identifier.issn0301-1623
dc.identifier.othervv_1032021
dc.identifier.otherav_59334cca-4f39-4d7f-a935-2fca369dc7f8
dc.identifier.urihttp://hdl.handle.net/20.500.12627/62765
dc.identifier.urihttps://doi.org/10.1007/s11255-007-9179-9
dc.description.abstractGlutathione S transferases (GSTT1, GSTM1, GSTP1) are enzymes that activate the detoxification of endogenous and exogenous agents. The genetic polymorphism in these genes may change the response of individuals to environmental toxicants. The genetic polymorphisms of GSTT1, GSTM1, GSTP1 have been studied extensively in the determination of individual cancer risks. Some studies showed a strong relationship between polymorphism of GSTs and superoxidedismutase enzymes. Using the polymerase chain reaction (PCR) the prevalence of genetic polymorphisms of GSTT1, GSTM1 and MnSOD (Manganese Superoxide Dismurase) was investigated in 104 cases and controls to seek any association with the risk of bladder cancer. The frequency of GSTT1 +/+ polymorphism was 65% (33/51) in the cases and 79% (42/53) in the controls. The frequency of the GSTM1 +/+ polymorphism was 33% (17/51) in the cases and 58% (31/53) in the controls. The frequency of the GSTM1 null genotype was 42% (22/53) in the controls and 68% (34/51) in the patients. The frequency of the SOD AA genotype was 36% (17/51) in the cases and 33% (19/53) in the controls. There was no association between the GSTT1 and SOD polymorphism and bladder cancer incidence. The incidence of the GSTM1 null genotype was increased in bladder cancer patients compared to controls (OR = 1.755, 95% CI = 1.119-2.751).
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectNefroloji
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectÜROLOJİ VE NEFROLOJİ
dc.subjectİç Hastalıkları
dc.titleThe investigation of GSTT1, GSTM1 and SOD polymorphism in bladder cancer patients
dc.typeMakale
dc.relation.journalINTERNATIONAL UROLOGY AND NEPHROLOGY
dc.contributor.department, ,
dc.identifier.volume39
dc.identifier.issue4
dc.identifier.startpage1043
dc.identifier.endpage1048
dc.contributor.firstauthorID185480


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record